MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
NCT05903092
Recruiting
The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enrolling on the study will receive a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana +3 locations
Conditions: Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer
Register for Updates
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
NCT05993949
Recruiting
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Palo Alto, California
Conditions: Lymphoblastic Leukemia
Register for Updates
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468
Recruiting
Multi-center study to collect large scale, multidimensional real-world data on patients undergoing carpal tunnel release (CTR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: The Orthopaedic Group P.C. (CTR-US), Foley, Alabama +36 locations
Conditions: Carpal Tunnel Syndrome, CTS
Register for Updates
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
NCT06323590
Recruiting
The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/01/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934
Recruiting
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/01/2025
Locations: Cahaba Dermatology & Skin Health Center- Site Number : 8401066, Birmingham, Alabama +304 locations
Conditions: Dermatitis Atopic
Register for Updates
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
NCT06466161
Recruiting
The diagnosis of hypertensive disease during pregnancy is predicated on strict blood pressure thresholds: 140/90 on at least two occasions measured four hours apart for both gestational hypertension and preeclampsia. An improvement in diagnostic accuracy of even 5mm Hg would be significant, as reflected by the US Association for the Advancement of Medical Instrumentation (AAMI), the British Hypertension Society, the European Society of Hypertension (ESH) Working Group on Blood Pressure (BP) Moni... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Prentice Women's Hospital, Chicago, Illinois
Conditions: Hypertension in Pregnancy, Hypertension, Obesity
Register for Updates
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195
Recruiting
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Baptist Health Medical Center, Little Rock, Arkansas +24 locations
Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Register for Updates
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)
NCT06625775
Recruiting
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: University of California Los Angeles, Los Angeles, California +10 locations
Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, HER2-Positive Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer
Register for Updates
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
NCT06676046
Recruiting
Background: The right amount of fats in the blood (cholesterol and triglycerides) are a key part of a healthy organism. Too much or too little of these fats may manifest as diseases (dyslipidemia). There are many causes for these abnormalities, but some are genetically determined and we would like to better understand the progression of these conditions over time. Objective: This natural history study aims to learn more about dyslipidemias; how they change over time; and how they respond to t... Read More
Gender:
ALL
Ages:
Between 10 years and 90 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dyslipidemia, Atherosclerosis
Register for Updates
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT06773026
Recruiting
This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A\>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and efficac... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
05/01/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Register for Updates
Examining the Relationship Between Ongoing Alcohol Use, Suicidal Thoughts and Behaviors and Related Constructs, and Behavioral Economic Decision-Making
NCT06845761
Recruiting
The purpose of this single groups trial is to (Aim 1) determine relationships between alcohol use, suicidal thoughts and behaviors (STBs), and behavioral economic decision-making in a community sample (N = 100) of alcohol using adults who are 18 years of age or older, (Aim 2) is to determine factors that predict engagement with a remote intervention (computer based training for cognitive behavioral therapy; CBT4CBT) for alcohol and its effects on alcohol use, STBs, and decision-making with those... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Alcohol Use, Suicidal Ideation/behavior
Register for Updates
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
NCT06914609
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Gender:
ALL
Ages:
Between 2 years and 50 years
Trial Updated:
05/01/2025
Locations: University of North Carolina at Chapel Hill School of Medicine, Carrboro, North Carolina
Conditions: Angelman Syndrome
Register for Updates